Dr. Yan Xie 谢彦
Chief Physician
Department of Lymphoma, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lymphoma, including stem cell transplantation.
Dr. Xie earned a doctoral degree in oncology from Peking University Health Science Center (1994–2004). Since 2004, Dr. Xie has worked in the Department of Lymphoma at Peking University Cancer Hospital. From 2009 to 2010, Dr. Xie was a visiting scholar at the University of Washington.
Name order: in Chinese the family name comes first (Xie Yan). Papers usually list the name as Yan Xie or Xie Y.
Selected publications
81 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Health Data Sci, 2026 (senior author): Personalizing Maintenance Rituximab in Follicular Lymphoma: A Machine Learning Framework for Risk-Benefit Optimization. PubMed 42591699
- Front Immunol, 2026 (senior author): Multi-omics analysis identifies GAA as an independent poor prognostic biomarker and candidate therapeutic target in angioimmunoblastic T-cell lymphoma. PubMed 42643572
- Blood Adv, 2026 (first author): Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. PubMed 40811825
- Ann Hematol, 2025 (senior author): Low levels of CD3 + and CD8 + T cells in peripheral blood can predict poor efficacy of first-line chemotherapy in patients with angioimmunoblastic T cell lymphoma. PubMed 40137981
- BMC Med, 2024 (senior author): Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial. PubMed 38454451
- Front Immunol, 2023 (senior author): Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study. PubMed 37081867
- Aging (Albany NY), 2022 (senior author): Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen. PubMed 35400665
- Ann Hematol, 2020 (first author): High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed classical Hodgkin lymphoma: a single center experience from China. PubMed 31980860
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion